Affiliations 

  • 1 Department of Life Science, School of Basic Science & Research (SBSR), Sharda University, Greater Noida, 201310, India
  • 2 Amity Institute of Molecular Medicine & Stem Cell Research (AIMMSCR), Amity University, Uttar Pradesh, Sec-125, Noida, 201313, India
  • 3 School of Pharmacy & Pharmaceutical Sciences, Ulster University, Cromore Road, Coleraine, Co. Londonderry, BT52 1SA, UK
  • 4 Department of Biotechnology, School of Engineering & Technology (SET), Sharda University, Greater Noida, 201310, India
  • 5 School of Pharmacy, University of Sunderland, Chester Road, Sunderland, SR1 3SD, UK
  • 6 Institute of Engineering & Technology, Lucknow, Uttar Pradesh, 226021, India
  • 7 Department of Biological Sciences, School of Basic & Applied Sciences, G.D. Goenka University, Education City, Sohna Road, Gurugram, Haryana, 122103, India
  • 8 Department of Biological Sciences, Faculty of Pure & Applied Sciences, University of Cyprus, Nicosia, Cyprus
  • 9 Department of Pharmaceutics & Pharmaceutical Technology, Pharos University in Alexandria, Egypt
  • 10 Department of Pharmacology & Therapeutics, College of Medicine & Health Sciences, PO Box-17666, United Arab Emirates University, Al Ain, UAE
  • 11 Department of Pharmaceutical Sciences, Maharshi Dayanand University, Rohtak, Haryana, 124001, India
  • 12 School of Pharmaceutical Sciences, Jaipur National University, Jagatpura, Jaipur, 302017, India
  • 13 School of Pharmaceutical Sciences, Lovely Professional University, Phagwara, Punjab, 144001, India
  • 14 Department of Life Sciences, School of Pharmacy, International Medical University (IMU), Kuala Lumpur, 57000, Malaysia
  • 15 Discipline of Pharmacy, Graduate School of Health, University of Technology Sydney, NSW, 2007, Australia
Nanomedicine (Lond), 2021 09;16(21):1905-1923.
PMID: 34348474 DOI: 10.2217/nnm-2021-0057

Abstract

The increasing burden of respiratory diseases caused by microbial infections poses an immense threat to global health. This review focuses on the various types of biofilms that affect the respiratory system and cause pulmonary infections, specifically bacterial biofilms. The article also sheds light on the current strategies employed for the treatment of such pulmonary infection-causing biofilms. The potential of nanocarriers as an effective treatment modality for pulmonary infections is discussed, along with the challenges faced during treatment and the measures that may be implemented to overcome these. Understanding the primary approaches of treatment against biofilm infection and applications of drug-delivery systems that employ nanoparticle-based approaches in the disruption of biofilms are of utmost interest which may guide scientists to explore the vistas of biofilm research while determining suitable treatment modalities for pulmonary respiratory infections.

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.